Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Inovio Pharmaceuticals Inc's Business Segments
Inovio Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Reportable99.5%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 0 | 99.5% |
Description of Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a biotechnology company focused on the development of innovative DNA medicines designed to treat cancer, infectious diseases, and other serious health conditions. The company was founded in 1979 by Dr. Joseph Kim and Dr. David Weiner, and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio's core technology platform is called Synthetic Vector and combines abilities in synthetic DNA design, immunology, and delivery optimization. The technology involves the use of a small circular DNA molecule called a plasmid, which is engineered to carry specific genetic instructions to trigger an immune response against certain diseases.
The company's lead product candidate, VGX-3100, is being developed as a treatment for cervical dysplasia caused by human papillomavirus (HPV). It is administered through intramuscular injection and is designed to stimulate a patient's immune system to recognize and eliminate HPV-infected cells. The vaccine has shown promising results in clinical trials, with the potential to be an effective therapy for cervical cancer.
Aside from VGX-3100, Inovio has a robust pipeline of product candidates targeting various indications. INO-5401 and INO-9012 are being developed in combination with other immunotherapies and immune checkpoint inhibitors for the treatment of glioblastoma (brain cancer) and advanced or metastatic solid tumors, respectively. INO-5151 and INO-1800 are designed to target hepatitis B virus (HBV) and are being developed as potential cures for chronic HBV infection.
In addition to its pipeline of product candidates, Inovio also collaborates with other pharmaceutical companies, academic institutions, and government agencies to advance its technologies and expand its research and development efforts. The company has entered into partnerships with organizations such as AstraZeneca, Regeneron Pharmaceuticals, and the National Institutes of Health (NIH). These collaborations help support the discovery, development, and commercialization of Inovio's product candidates.
Inovio's technology has several advantages over traditional vaccines and therapies. Its DNA-based platform offers potential for rapid development and manufacturing, scalability, and the ability to generate immune responses against specific disease targets. Additionally, the platform enables the inclusion of multiple antigens in a single vaccine, allowing for the development of combination therapies targeting multiple cancers or infectious diseases simultaneously.
The company is dedicated to global health and has initiatives to address infectious diseases that disproportionately affect developing countries, such as Zika, Ebola, and HIV. Inovio's vaccine candidates for these diseases have shown promising results in preclinical and early-stage clinical trials.
Inovio Pharmaceuticals Inc has a strong team of scientists, researchers, and business professionals dedicated to advancing the field of DNA medicines. The company continues to focus on innovation, collaboration, and the development of transformative therapies to improve patient outcomes and address unmet medical needs.
Inovio's core technology platform is called Synthetic Vector and combines abilities in synthetic DNA design, immunology, and delivery optimization. The technology involves the use of a small circular DNA molecule called a plasmid, which is engineered to carry specific genetic instructions to trigger an immune response against certain diseases.
The company's lead product candidate, VGX-3100, is being developed as a treatment for cervical dysplasia caused by human papillomavirus (HPV). It is administered through intramuscular injection and is designed to stimulate a patient's immune system to recognize and eliminate HPV-infected cells. The vaccine has shown promising results in clinical trials, with the potential to be an effective therapy for cervical cancer.
Aside from VGX-3100, Inovio has a robust pipeline of product candidates targeting various indications. INO-5401 and INO-9012 are being developed in combination with other immunotherapies and immune checkpoint inhibitors for the treatment of glioblastoma (brain cancer) and advanced or metastatic solid tumors, respectively. INO-5151 and INO-1800 are designed to target hepatitis B virus (HBV) and are being developed as potential cures for chronic HBV infection.
In addition to its pipeline of product candidates, Inovio also collaborates with other pharmaceutical companies, academic institutions, and government agencies to advance its technologies and expand its research and development efforts. The company has entered into partnerships with organizations such as AstraZeneca, Regeneron Pharmaceuticals, and the National Institutes of Health (NIH). These collaborations help support the discovery, development, and commercialization of Inovio's product candidates.
Inovio's technology has several advantages over traditional vaccines and therapies. Its DNA-based platform offers potential for rapid development and manufacturing, scalability, and the ability to generate immune responses against specific disease targets. Additionally, the platform enables the inclusion of multiple antigens in a single vaccine, allowing for the development of combination therapies targeting multiple cancers or infectious diseases simultaneously.
The company is dedicated to global health and has initiatives to address infectious diseases that disproportionately affect developing countries, such as Zika, Ebola, and HIV. Inovio's vaccine candidates for these diseases have shown promising results in preclinical and early-stage clinical trials.
Inovio Pharmaceuticals Inc has a strong team of scientists, researchers, and business professionals dedicated to advancing the field of DNA medicines. The company continues to focus on innovation, collaboration, and the development of transformative therapies to improve patient outcomes and address unmet medical needs.
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies and vaccines using its proprietary DNA medicine platform. The company primarily specializes in immunotherapies to treat cancer and infectious diseases. Below is an extensive overview of the segments, products, and services offered by Inovio Pharmaceuticals.
Segments
1. Oncology:
- The oncology segment concentrates on the development of therapies aimed at treating various types of cancer by harnessing the body’s immune system. Inovio’s approach typically involves producing immune responses that can target cancer cells, with the goal of achieving tumor destruction and improving patient outcomes.
2. Infectious Diseases:
- This segment encompasses the development of vaccines against viral and bacterial pathogens. The focus is on creating preventative and therapeutic vaccines to combat infectious diseases, leveraging cutting-edge DNA technology to induce robust immune responses.
3. Research and Development (R&D):
- R&D is a core segment of Inovio pharmaceuticals, wherein the company invests in the discovery and development of new products and technologies. This includes both preclinical and clinical trials designed to evaluate the safety and efficacy of its therapeutic and vaccination candidates.
Products
1. Cancer Immunotherapies:
- INO-1400 Series: Inovio is developing various products under the INO-1400 series, which includes immunotherapy candidates designed to treat solid tumors by stimulating the bodys immune response.
- INO-5401: This is another immunotherapeutic candidate targeting glioblastoma multiforme, a type of aggressive brain cancer.
2. Infectious Disease Vaccines:
- INO-4800: This candidate is aimed at providing immunity against COVID-19. It is a DNA vaccine designed to generate specific immune responses against the virus responsible for the pandemic.
- VGX-3100: This is designed for the treatment of cervical dysplasia caused by human papillomavirus (HPV). It aims to reverse the disease’s progression by inducing an immune response.
- INO-1800: Focused on developing a vaccine for the treatment of hepatitis B virus (HBV) infection.
Services
1. Clinical Development Services:
- Inovio offers expertise in navigating the complexities of clinical trials, including design, implementation, and management of such studies. Their ability to efficiently execute clinical programs is a significant aspect of their service offering.
2. Regulatory Affairs Support:
- The company maintains a knowledgeable regulatory affairs team that aids in obtaining necessary approvals for clinical studies and subsequent product launches as it interacts with health authorities such as the FDA and EMA.
3. Collaborative Partnerships:
- Inovio frequently engages in partnerships with academic institutions, governmental bodies, and pharmaceutical companies to advance its developmental programs. These collaborations can help in sharing resources, expertise, and technology to facilitate research and development efforts.
4. Technology Licensing:
- Inovio’s proprietary DNA technology is available for licensing to other companies, enabling them to develop additional therapies or vaccines using Inovios platform. This includes applications in other therapeutic areas beyond those currently pursued by Inovio itself.
5. Patient Advocacy and Education:
- Inovio is also involved in initiatives aimed at educating patients and healthcare providers about their products, the underlying diseases, and the potential benefits of new therapies under development.
Conclusion
Inovio Pharmaceuticals is an innovative player in the field of biotechnology, leveraging its unique DNA medicine platform to create groundbreaking therapies aimed at cancer and infectious diseases. Its commitment to R&D, robust pipeline of vaccine candidates, and efforts in clinical development and regulatory affairs reflect a holistic approach to advancing healthcare solutions. Through collaborations and partnerships, Inovio aims to expand its impact in the biopharmaceutical space while providing services that support its mission.
Segments
1. Oncology:
- The oncology segment concentrates on the development of therapies aimed at treating various types of cancer by harnessing the body’s immune system. Inovio’s approach typically involves producing immune responses that can target cancer cells, with the goal of achieving tumor destruction and improving patient outcomes.
2. Infectious Diseases:
- This segment encompasses the development of vaccines against viral and bacterial pathogens. The focus is on creating preventative and therapeutic vaccines to combat infectious diseases, leveraging cutting-edge DNA technology to induce robust immune responses.
3. Research and Development (R&D):
- R&D is a core segment of Inovio pharmaceuticals, wherein the company invests in the discovery and development of new products and technologies. This includes both preclinical and clinical trials designed to evaluate the safety and efficacy of its therapeutic and vaccination candidates.
Products
1. Cancer Immunotherapies:
- INO-1400 Series: Inovio is developing various products under the INO-1400 series, which includes immunotherapy candidates designed to treat solid tumors by stimulating the bodys immune response.
- INO-5401: This is another immunotherapeutic candidate targeting glioblastoma multiforme, a type of aggressive brain cancer.
2. Infectious Disease Vaccines:
- INO-4800: This candidate is aimed at providing immunity against COVID-19. It is a DNA vaccine designed to generate specific immune responses against the virus responsible for the pandemic.
- VGX-3100: This is designed for the treatment of cervical dysplasia caused by human papillomavirus (HPV). It aims to reverse the disease’s progression by inducing an immune response.
- INO-1800: Focused on developing a vaccine for the treatment of hepatitis B virus (HBV) infection.
Services
1. Clinical Development Services:
- Inovio offers expertise in navigating the complexities of clinical trials, including design, implementation, and management of such studies. Their ability to efficiently execute clinical programs is a significant aspect of their service offering.
2. Regulatory Affairs Support:
- The company maintains a knowledgeable regulatory affairs team that aids in obtaining necessary approvals for clinical studies and subsequent product launches as it interacts with health authorities such as the FDA and EMA.
3. Collaborative Partnerships:
- Inovio frequently engages in partnerships with academic institutions, governmental bodies, and pharmaceutical companies to advance its developmental programs. These collaborations can help in sharing resources, expertise, and technology to facilitate research and development efforts.
4. Technology Licensing:
- Inovio’s proprietary DNA technology is available for licensing to other companies, enabling them to develop additional therapies or vaccines using Inovios platform. This includes applications in other therapeutic areas beyond those currently pursued by Inovio itself.
5. Patient Advocacy and Education:
- Inovio is also involved in initiatives aimed at educating patients and healthcare providers about their products, the underlying diseases, and the potential benefits of new therapies under development.
Conclusion
Inovio Pharmaceuticals is an innovative player in the field of biotechnology, leveraging its unique DNA medicine platform to create groundbreaking therapies aimed at cancer and infectious diseases. Its commitment to R&D, robust pipeline of vaccine candidates, and efforts in clinical development and regulatory affairs reflect a holistic approach to advancing healthcare solutions. Through collaborations and partnerships, Inovio aims to expand its impact in the biopharmaceutical space while providing services that support its mission.